PAYSPaysign, Inc.
The schedule
- Wed11Nov
The Q3 2026 earnings release is a key event that will provide insight into the company's performance during the third quarter of 2026. This event is expected to include guidance for the full year of 2027, which can significantly influence investor sentiment and stock price movement. The release will be closely watched by market participants for any signs of improved financial performance or strategic direction.
- Sun14Feb
The Q4 2026 earnings release is a critical event that will offer a comprehensive view of the company's performance for the fourth quarter of 2026. This event is anticipated to include forward-looking guidance for the full year of 2027, which can have a substantial impact on the stock's valuation and market perception. Investors will be looking for clear signals of growth and operational efficiency.
- Wed12May
The Q1 2027 earnings release is an important event that will provide an update on the company's performance during the first quarter of 2027. This release is expected to include guidance for the full year of 2027, which can shape investor expectations and influence the stock's direction. The results will be a key indicator of the company's ability to sustain growth and meet financial targets.
- Thu5Aug
The Q2 2027 earnings release is a pivotal event that will provide an assessment of the company's performance during the second quarter of 2027. This event is likely to include guidance for the full year of 2027, which can have a major impact on the stock's trajectory and market confidence. The results will be closely analyzed for any signs of continued growth and strategic progress.
Past
- Thu6Aug
Actual outcome: Bull
Paysign beat EPS estimates with record revenue, driven by expansion in Patient Affordability and improved plasma donor operations. The company raised full-year guidance, sending shares above the bull target despite a minor post-earnings pullback.
Paysign beat EPS estimates with record revenue, driven by expansion in Patient Affordability and improved plasma donor operations. The company raised full-year guidance, sending shares above the bull target despite a minor post-earnings pullback.
- Wed1Jul
Actual outcome: Bull · $8.83 at outcome
PAYS delivered positive updates regarding its expansion into new verticals and successful client diversification. The confirmation of smooth onboarding processes without delays reassured investors of the company's growth trajectory, driving shares up to the bull target.
PAYS delivered positive updates regarding its expansion into new verticals and successful client diversification. The confirmation of smooth onboarding processes without delays reassured investors of the company's growth trajectory, driving shares up to the bull target.
- Wed13May
Actual outcome: Bull · $7.11 at outcome
Paysign reported its strongest start to a year in company history, with Q1 2026 revenue surging 50.8% year-over-year to $28 million and beating management guidance. The robust top-line growth and sharp margin expansion, driven by its patient affordability business becoming the largest revenue contributor, validated the operational leverage thesis and drove the stock well past the $6.70 bull target.
Paysign reported its strongest start to a year in company history, with Q1 2026 revenue surging 50.8% year-over-year to $28 million and beating management guidance. The robust top-line growth and sharp margin expansion, driven by its patient affordability business becoming the largest revenue contributor, validated the operational leverage thesis and drove the stock well past the $6.70 bull target.
- Wed25Mar
Actual outcome: Bull · $5.90 at outcome
Paysign reported Q4 2025 earnings that met EPS expectations and beat sales estimates, driven by 40% revenue growth and rapid expansion in its patient affordability platform. The stock surged well past the bull target as the company's strong forward guidance and significant margin expansion signaled continued exceptional growth to investors.
Paysign reported Q4 2025 earnings that met EPS expectations and beat sales estimates, driven by 40% revenue growth and rapid expansion in its patient affordability platform. The stock surged well past the bull target as the company's strong forward guidance and significant margin expansion signaled continued exceptional growth to investors.
